December 3, 2021 @ 7:00 am – December 4, 2021 @ 4:00 pm UTC+1
This Event has passed
Dear National Delegates & Members from all countries of the European Region,
THE EAP WINTER MEETING 2021 WILL TAKE PLACE VIRTUALLY
We would like to inform you that the EAP Winter Meeting will turn virtual. Although we were eager to meet you in person, the decision was made with the best interest, health, and safety of National Delegates in mind.
Virtual registration is free of charge.
Primary Care Council
Chair: Prof. Zachi Grossman / Stefano del Torso
Break |
Secondary – Tertiary Care Council Chair: Prof. Berthold Koletzko |
European Board of Paediatrics (including elections) Chair: Dr. Robert Ross Russell |
Coffee Break
EAP – General Assembly Chair: Prof. Adamos Hadjipanayis |
We look forward to welcoming you to the meeting and we regret that it won’t be in-person this time.
Warm Regards,
Prof. Adamos Hadjipanayis (EAP President)
New ways to test high-risk medical devices.
Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.
It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.